LKB1 在鼻咽癌中的表达及与化疗敏感性的关系

目的 研究鼻咽癌（NPC）组织中LKB1 的表达，分析其与临床病理因素、化疗敏感性及预后的关系。 方法 采用免疫组织化学EnVision 二步法检测74 例NPC 组织标本中LKB1 的表达，根据其表达水平将标本 分为LKB1 低表达组和LKB1 高表达组。采用ATP 生物荧光肿瘤体外药敏检测技术体外检测NPC 患者肿瘤 细胞对8 种常见化疗药物的敏感性。结合患者随访资料，分析LKB1 表达与临床病理因素、化疗敏感性及预 后的关系。结果 在NPC 组织中，LKB1 蛋白在细胞核和细胞质均有表达，呈棕黄色；LKB1 高、低表达组间 患者年龄、病理组织学类型、TNM 分期及临床分期比较，差异无统计学意义（P >0.05），仅性别比较差异有 统计学意义（P <0.05）。NPC 细胞对8 种化疗药物敏感性不同（P <0.05）。在8 种化疗药物中，仅LKB1 低表 达组的. 环磷酰胺耐药率高于LKB1 高表达组（P <0.05），其余差异无统计学意义（P >0.05）。LKB1 低表达组 患者的死亡率高于高表达组（P <0.05）。两组患者转移和复发率比较，差异无统计学意义（P >0.05）。LKB1 低表达组患者的总生存率低于高表达组（P <0.05）。两组间无进展生存率比较，差异无统计学意义（P >0.05）。 结论 LKB1 表达水平与NPC 患者的生存率有关，并且可能与环磷酰胺的耐药有关。

Expression of LKB1 in nasopharyngeal carcinoma and its relationship with chemosensitivity

Objective To research the expression of liver kinase B1 (LKB1) in nasopharyngeal carcinoma (NPC) tissues and analyze its relationships with clinicopathological parameters, chemosensitivity and prognosis. Methods The expression of LKB1 in 74 NPC tissue samples was detected by EnVision two-step immunohistochemical assay, and then the NPC tissue samples were divided into the LKB1 low-expression group and the LKB1 high-expression group. The in vitro chemosensitivity of NPC cells to 8 common chemotherapeutic drugs was detected by ATP-fluorescence in vitro susceptibility assay. Combined with follow-up data of the patients, the relationships of the expression of LKB1 with clinicopathological parameters, chemosensitivity and prognosis were analyzed. Results LKB1 was expressed in both nuclei and cytoplasm in the NPC cells, showing a brownish yellow color. There was no significant difference in the age, histopathological type, TNM stage or clinical stage between the two groups (P > 0.05); but there was statistical difference in gender between the two groups (P < 0.05). The chemosensitivity of NPC cells to the 8 chemotherapeutic agents was different (P < 0.05). The rate of resistance to cyclophosphamide in the LKB1 low-expression group was higher than that in the LKB1 high-expression group (P < 0.05), and the rates of resistance to the remaining drugs were not statistically different between the two groups (P > 0.05). The mortality of the LKB1 low-expression group was higher than that of the LKB1 high-expression group (P < 0.05). There was no significant difference in metastasis or recurrence rate between the two groups (P > 0.05). The overall survival rate of the patients in the LKB1 low-expression group was lower than that in the high-expression group (P < 0.05), but there was no significant difference in the progression-free survival rate between the two groups (P > 0.05). Conclusions Low expression of LKB1 is related to the survival rate of NPC patients and may be related to the resistance to cyclophosphamide.